Roy Gulick
机构: Professor of Medicine, Weill Cornell
每年引用次数
引用次数
引用: 25,736
H-指数: 67
I10-指数 : 168
出版物: 298
FACULTY DISCLOSURE
Lester N Wright , Charles J Moehs , Sarah J Walker , Abigail V Gallucci
Design issues in initial HIV-treatment trials: focus on ACTG A5095.
Daniel R. Kuritzkes , Heather J. Ribaudo , Cecilia M. Shikuma , Bruce R. Schackman
Antiviral Therapy 11 ( 6) 751 -760
12
2006
Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy.
Graeme Moyle , Ole Kirk , Joseph J. Eron , Andrew N. Phillips
Antiviral Therapy 7 ( 4) 271 -281
21
2002
Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults.
Sharon A. Riddler , Eric S. Daar , Jeffrey L. Lennox , Yuki Bradford
PLOS Genetics 17 ( 4)
8
2021
New drugs for HIV therapy.
Roy M. Gulick , Schlomo Staszewski
AIDS 16
10
2002
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
Anthony R. Cillo , Benedict B. Hilldorfer , Christina M. Lalama , John E. McKinnon
AIDS 29 ( 16) 2121 -2129
21
2015
Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095
Li Li , Joseph J. Eron , Heather Ribaudo , Roy M. Gulick
Journal of the American Statistical Association 107 ( 498) 542 -554
12
2012
Causes of HIV treatment failure
Roy M. Gulick
Birkhäuser, Basel 159 -194
2004
The Uncertain Role of Corticosteroids in the Treatment of COVID-19.
Grant B. Ellsworth , Marshall J. Glesby , Roy M. Gulick
JAMA Internal Medicine 181 ( 1) 140 -140
2
2021
New HIV drugs: 2018 and beyond.
Roy M. Gulick
Current Opinion in Hiv and Aids 13 ( 4) 291 -293
3
2018
HIV treatment and prevention 2019: current standards of care.
Nittaya Phanuphak , Roy M. Gulick
Current Opinion in Hiv and Aids 15 ( 1) 4 -12
7
2020
Treatment of Viral Infections in the Human Immunodeficiency Virus-Infected Patient
Roy M. Gulick , Clyde S. Crumpacker
Clinical Approach to Infection in the Compromised Host 469 -490
1
1994
Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo
Chad Nusbaum , Daniel R. Kuritzkes , Athe M. N. Tsibris , Bette Korber
PLoS ONE 4 ( 5) e5683
207
2009
Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells.
Dominique B. Figueroa , Erin P. Madeen , Joseph Tillotson , Paul Richardson
AIDS Research and Human Retroviruses 34 ( 5) 421 -429
3
2018
The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients.
Timothy J. Wilkin , Heather R. Ribaudo , Allan R. Tenorio , Roy M. Gulick
Hiv Clinical Trials 11 ( 6) 351 -358
27
2010
Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development.
Bethany L. Morris , Callie A. Scott , Timothy J. Wilkin , Paul E. Sax
Hiv Clinical Trials 13 ( 1) 1 -10
3
2012
Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359.
Richard H. Haubrich , Hongyu Jiang , Ronald Swanstrom , Michael Bates
Hiv Clinical Trials 8 ( 2) 63 -67
3
2007
Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients.
Robert L. Murphy , Barbara A. da Silva , Charles B. Hicks , Joseph J. Eron
Hiv Clinical Trials 9 ( 1) 1 -10
65
2008
Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s).
David B. Clifford , Scott Evans , Yijun Yang , Edward P. Acosta
Hiv Clinical Trials 10 ( 6) 343 -355
70
2009